New Zeland. Pharmaceutical company fined for fraud

Wellington, 3 feb (PL) La Commissione Commercio della Nuova Zelanda ha confermato oggi l’ammenda inflitta alla società farmaceutica Reckitt Benckiser, produttore di Nurofen, un farmaco ingannevole.

A court in the city of Auckland fined the company more than 785,000 $ for misleading consumers.

Secondo la Commissione, Reckitt Benckiser ha ammesso che tra il 2011 e il 2015 ha dato informazioni fuorvianti circa la natura, le caratteristiche e l’idoneità di una gamma di prodotti di Nurofen.

The Nurofen line of pain relievers is marketed for migraines, back pain, menstrual disorders, and stress-induced headaches.

However, all were found to contain the same drug base, 342 milligrams of ibuprofen lysine.

The ruling follows an Australian court fined Reckitt Benckiser $ 4,400,000 in mid-December for misleading the consumer.

The company was found guilty of misinforming the consumer, assuring that certain Nurofen painkillers would relieve a specific pain.

Prensa Latina – 03/02/2017